Quick Summary:
- Pfizer (PFE, Financial) maintains a stable dividend with a forward yield of 7.68%.
- Analysts project a potential 30.09% upside based on average price targets.
- GuruFocus estimates indicate a 27.6% upside relative to its GF Value.
Steady Income with Pfizer's Dividend
Pfizer Inc. (PFE) continues to attract income-focused investors with its consistent quarterly dividend of $0.43 per share, translating to an attractive forward yield of 7.68%. This dividend is scheduled for payment on June 13 to shareholders who are on record as of May 9, with the ex-dividend date also on May 9.
Analyst Projections and Price Targets
The outlook among Wall Street analysts remains optimistic for Pfizer. According to price targets set by 19 analysts, the one-year average target price stands at $29.13, with estimates ranging from a high of $41.43 to a low of $22.00. This average target presents a compelling potential upside of 30.09% from the current share price of $22.39. Investors looking for more granular details can explore the Pfizer Inc (PFE, Financial) Forecast page.
Brokerage Firm Recommendations
Pfizer's (PFE, Financial) current standing with 23 brokerage firms suggests a "Hold" status, reflected in an average recommendation score of 2.6 on a 1 to 5 scale—where 1 symbolizes a Strong Buy and 5 indicates a Sell.
Evaluating Pfizer's GF Value
GuruFocus provides its own valuation insights with the estimated GF Value for Pfizer Inc. (PFE, Financial) projected at $28.57 in one year. This figure implies a potential upside of 27.6% from the current trading price of $22.39. The GF Value is derived from historical trading multiples, past business growth, and future performance projections. For further insights, visit the Pfizer Inc (PFE) Summary page.
Investors are encouraged to consider both the steady income potential from dividends and the upside prospects as part of their investment strategy in Pfizer.
